These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 9434102

  • 1. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.
    Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD, Bennett JP.
    Biochim Biophys Acta; 1997 Nov 28; 1362(1):77-86. PubMed ID: 9434102
    [Abstract] [Full Text] [Related]

  • 2. Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions.
    Smith TS, Bennett JP.
    Brain Res; 1997 Aug 15; 765(2):183-8. PubMed ID: 9313890
    [Abstract] [Full Text] [Related]

  • 3. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Singh A, Verma P, Balaji G, Samantaray S, Mohanakumar KP.
    Neurochem Int; 2016 Oct 15; 99():221-232. PubMed ID: 27395789
    [Abstract] [Full Text] [Related]

  • 4. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease.
    Ozsoy O, Seval-Celik Y, Hacioglu G, Yargicoglu P, Demir R, Agar A, Aslan M.
    Neurochem Int; 2011 Oct 15; 59(5):664-70. PubMed ID: 21736911
    [Abstract] [Full Text] [Related]

  • 5. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R, Choudhury A, Kumar S, Giri A, Sandhir R, Borah A.
    PLoS One; 2017 Oct 15; 12(2):e0171285. PubMed ID: 28170429
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modulation of mitochondrial phenotypes by endurance exercise contributes to neuroprotection against a MPTP-induced animal model of PD.
    Jang Y, Kwon I, Song W, Cosio-Lima LM, Taylor S, Lee Y.
    Life Sci; 2018 Sep 15; 209():455-465. PubMed ID: 30144449
    [Abstract] [Full Text] [Related]

  • 10. Disrupted mitochondrial electron transport function increases expression of anti-apoptotic bcl-2 and bcl-X(L) proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress.
    Veech GA, Dennis J, Keeney PM, Fall CP, Swerdlow RH, Parker WD, Bennett JP.
    J Neurosci Res; 2000 Sep 15; 61(6):693-700. PubMed ID: 10972966
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase.
    Zhang J, Graham DG, Montine TJ, Ho YS.
    J Neuropathol Exp Neurol; 2000 Jan 15; 59(1):53-61. PubMed ID: 10744035
    [Abstract] [Full Text] [Related]

  • 13. Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.
    Franco J, Prediger RD, Pandolfo P, Takahashi RN, Farina M, Dafre AL.
    Life Sci; 2007 Apr 24; 80(20):1906-14. PubMed ID: 17382353
    [Abstract] [Full Text] [Related]

  • 14. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.
    Cassarino DS, Fall CP, Smith TS, Bennett JP.
    J Neurochem; 1998 Jul 24; 71(1):295-301. PubMed ID: 9648878
    [Abstract] [Full Text] [Related]

  • 15. 2, 2'- and 4, 4'-Cyanines are transporter-independent in vitro dopaminergic toxins with the specificity and mechanism of toxicity similar to MPP⁺.
    Kadigamuwa CC, Le VQ, Wimalasena K.
    J Neurochem; 2015 Nov 24; 135(4):755-67. PubMed ID: 26094622
    [Abstract] [Full Text] [Related]

  • 16. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain.
    Thiffault C, Aumont N, Quirion R, Poirier J.
    J Neurochem; 1995 Dec 24; 65(6):2725-33. PubMed ID: 7595571
    [Abstract] [Full Text] [Related]

  • 17. Functioning of the Antioxidant Defense System in Rotenone-Induced Parkinson's Disease.
    Kryl'skii ED, Razuvaev GA, Potapova TN, Akinina AI, Nihaev LE.
    Bull Exp Biol Med; 2021 Oct 24; 171(6):716-721. PubMed ID: 34705173
    [Abstract] [Full Text] [Related]

  • 18. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.
    Wang YQ, Wang MY, Fu XR, Peng-Yu, Gao GF, Fan YM, Duan XL, Zhao BL, Chang YZ, Shi ZH.
    Free Radic Res; 2015 Oct 24; 49(9):1069-80. PubMed ID: 25968939
    [Abstract] [Full Text] [Related]

  • 19. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
    Kanagaraj N, Beiping H, Dheen ST, Tay SS.
    Neuroscience; 2014 Jul 11; 272():167-79. PubMed ID: 24792712
    [Abstract] [Full Text] [Related]

  • 20. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
    Liu L, Peritore C, Ginsberg J, Shih J, Arun S, Donmez G.
    Behav Brain Res; 2015 Mar 15; 281():215-21. PubMed ID: 25541039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.